| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/15/2011 | EP2331142A2 Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells |
| 06/15/2011 | EP2331141A2 Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
| 06/15/2011 | EP2331137A1 New combination of active ingredients containing an alpha-1antagonist and a pde 4 inhibitor |
| 06/15/2011 | EP2331135A1 Methods of treating and preventing glucose toxicity |
| 06/15/2011 | EP2331131A1 Treating cancer by modulating rna helicases |
| 06/15/2011 | EP2331106A1 Nucleoside analogues useful as positron emission tomography (pet) imaging agents |
| 06/15/2011 | EP2331104A2 Method of inducing an anti-viral immune response |
| 06/15/2011 | EP2331103A1 Nuclear factor kappa b pathway inhibitor composition and use of same |
| 06/15/2011 | EP2331102A1 Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol and an nsaid |
| 06/15/2011 | EP2331101A1 Monocyclic amide cgrp receptor antagonists |
| 06/15/2011 | EP2331100A2 Methods and kits for treating cluster headache disorders |
| 06/15/2011 | EP2331099A1 Pharmaceutical compositions for the treatment of diabetes mellitus |
| 06/15/2011 | EP2331098A1 Methods for the administration of iloperidone |
| 06/15/2011 | EP2331097A1 Methods for treating cns disorders |
| 06/15/2011 | EP2331096A1 Dabigatran in tumour therapy |
| 06/15/2011 | EP2331095A1 Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| 06/15/2011 | EP2331094A2 Novel anti-arrhythmia agent |
| 06/15/2011 | EP2331093A1 Compounds, compositions and methods for reducing toxicity and treating or preventing diseases |
| 06/15/2011 | EP2331092A2 Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer |
| 06/15/2011 | EP2331091A1 Pharmaceutical combination of 1-(2-tetrahydrofuryl)-5-fluorouracil and caffeic acid phenethyl ester for oral treating of tumors |
| 06/15/2011 | EP2331090A1 Stable liquid antibody formulation |
| 06/15/2011 | EP2331089A2 Uses of sesquiterpene derivatives |
| 06/15/2011 | EP2331088A1 Compositions and methods for treating psychiatric disorders |
| 06/15/2011 | EP2331087A1 Pharmaceutical combination comprising 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3 diol and paracetamol |
| 06/15/2011 | EP2331084A1 Pharmaceutical compositions comprising amorphous esomeprazole, dosage forms and process thereof |
| 06/15/2011 | EP2331082A1 Solvent extraction microencapsulation with tunable extraction rates |
| 06/15/2011 | EP2331080A1 Pharmaceutical compositions configured to deter dosage form splitting |
| 06/15/2011 | EP2331079A2 Pharmaceutical formulation |
| 06/15/2011 | EP2331076A1 Chewable sustained release formulations |
| 06/15/2011 | EP2331074A1 Granulates, process for preparing them and pharmaceutical products containing them |
| 06/15/2011 | EP2331068A1 Benzimidazole anthelmintic compositions |
| 06/15/2011 | EP2331067A1 Progestin-containing drug delivery system |
| 06/15/2011 | EP2331066A1 Mucomimetic compositions and uses therefore |
| 06/15/2011 | EP2331065A1 Modified release emulsions for application to skin or vaginal mucosa |
| 06/15/2011 | EP2331056A1 Use of an n-acyl amino acid selected from among n-palmitoyl alanine, n-palmitoyl glycine, n-palmitoyl isoleucine, and n-cocoyl alanine as an active agent controlling the proportion of basal keratinocytes of the human skin epidermis and expressing the nuclear form of surviving, and anti-aging cosmetic composition comprising same |
| 06/15/2011 | EP2331048A1 Oligomeric biosurfactants in dermatocosmetic compositions |
| 06/15/2011 | EP2330911A1 Natural preservative alternatives and compositions containing same |
| 06/15/2011 | EP2330909A1 Chemical compounds |
| 06/15/2011 | EP2330908A1 Fluorescent cdk inhibitors for treatment of cancer |
| 06/15/2011 | EP2330903A1 Methods to treat pain using an alpha-2 adrenergic agonist and an endothelin antagonist |
| 06/15/2011 | EP2330902A1 Chemical compounds |
| 06/15/2011 | EP2330901A1 Treatment for leukemia and idiopathic aplastic anemia |
| 06/15/2011 | EP2330899A1 Methods for treating neuropathic pain |
| 06/15/2011 | EP2330897A1 Ngal-binding siderophores and use thereof to treat iron deficiency and iron overload |
| 06/15/2011 | EP2330896A1 Antinecrotic activity of alpha 1-antitrypsin |
| 06/15/2011 | EP2330895A1 Short acting benzothiazepine calcium channel blockers and uses thereof |
| 06/15/2011 | EP2330894A1 Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors |
| 06/15/2011 | EP2330893A1 Deep lung pulmonary delivery of treprostinil |
| 06/15/2011 | EP2330892A1 Methods of treatment using ammonia-scavenging drugs |
| 06/15/2011 | EP2234492B1 Pharmaceutical composition containing an n-phenylpyrazole derivative and glycofurol, use for the preparation of a topical veterinary medicament for combating fleas |
| 06/15/2011 | EP2203430B1 N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors |
| 06/15/2011 | EP2187878B1 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas |
| 06/15/2011 | EP2185561B1 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo(1,2-a)-diazepine-7-carboxamide derivatives, preparation and therapeutic use thereof |
| 06/15/2011 | EP2144906B1 Heterocycles as orexin antagonists |
| 06/15/2011 | EP2104535B9 Compounds and compositions as channel activating protease inhibitors |
| 06/15/2011 | EP2097434B1 Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis c virus |
| 06/15/2011 | EP2081939B1 Benzimidazole derivatives as selective acid pump inhibitors |
| 06/15/2011 | EP2074086B1 Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
| 06/15/2011 | EP2007769B1 Dimers of artemisinin derivatives, preparation thereof and therapeutic use thereof |
| 06/15/2011 | EP1937650B1 Heterocyclic compounds |
| 06/15/2011 | EP1899346B1 Pyrrolotriazine compounds useful as kinase inhibitors |
| 06/15/2011 | EP1871890B1 Methods and devices for delivering a therapeutic product to the ocular sphere of a subject |
| 06/15/2011 | EP1851225B1 Pyrazolo-pyrimidine derivatives as mglur2 antagonists |
| 06/15/2011 | EP1838718B1 Pyrrolopyrazoles, potent kinase inhibitors |
| 06/15/2011 | EP1827441B1 Combinations for the treatment of diseases involving cell proliferation |
| 06/15/2011 | EP1827413B1 Use of cyclodextrin complexes containing lipoic acid |
| 06/15/2011 | EP1812404B1 Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents |
| 06/15/2011 | EP1784399B1 Pyrimidine derivatives |
| 06/15/2011 | EP1771454B1 Hepatitis c inhibitor peptide analogs |
| 06/15/2011 | EP1761529B3 Pyrrolopyridine derivatives and their use as crth2 antagonists |
| 06/15/2011 | EP1749030B1 A diabody which specifically binds streptococcus surface antigen i/ii and methods of use thereof |
| 06/15/2011 | EP1717229B1 Novel cyclic compound having 4-pyridylalkylthio group having (un)substituted amino introduced therein |
| 06/15/2011 | EP1664022B1 2-substituted benzimidazole piperidine analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders |
| 06/15/2011 | EP1631251B1 Delayed release tablet with defined core geometry |
| 06/15/2011 | EP1622616B1 Inhibitors of akt activity |
| 06/15/2011 | EP1619185B1 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof |
| 06/15/2011 | EP1598371B1 Medicinal composition for ophthalmic use containing acetylated hyaluronic acid |
| 06/15/2011 | EP1597585B1 Method for selecting a candidate drug compound |
| 06/15/2011 | EP1578751B1 Pyrrolopyrimidine derivatives |
| 06/15/2011 | EP1404710B1 Identification of ses-3 (spr-5) in c. elegans and the uses of the same |
| 06/15/2011 | EP1389618B1 Pyrazolo 1,5-a pyridines and medicines containing the same |
| 06/15/2011 | EP1349558B1 Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity |
| 06/15/2011 | EP1330456B1 N8,n13 -disubstituted quino[4,3,2-kl]acridinium salts as therapeutic agents |
| 06/15/2011 | EP1213971B1 Improving condition of elderly pets |
| 06/15/2011 | EP1175400B1 Renin inhibitors |
| 06/15/2011 | EP1052254B1 Nitrogenous heterocyclic derivatives and medicine thereof |
| 06/15/2011 | EP0835110B2 Use of (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
| 06/15/2011 | CN201861992U Multiple coating mirco-capsulation lactic acid bacteria (MCM-LAB) structure |
| 06/15/2011 | CN1997621B Crystalline forms of (-)-(1r,2r)-3-(3-dimethyl amino-1-ethyl-2-methyl propyl)-phenol hydrochloride |
| 06/15/2011 | CN1995056B Curcumenol glucoside compound and its preparation method and uses |
| 06/15/2011 | CN1985842B Oral azithromycin resin suspension and its preparing method |
| 06/15/2011 | CN1974591B SiRNA expression template for treating liver necrosis and liver fibrosis |
| 06/15/2011 | CN1969874B Externally applied pharmaceutical composition of abafungin |
| 06/15/2011 | CN1968942B Novel tetracyclic tetrahydrofuran derivatives |
| 06/15/2011 | CN1956964B Tetrahydro-indazole cannabinoid modulators |
| 06/15/2011 | CN1946714B Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors |
| 06/15/2011 | CN1939380B Heat-clearing analgesic medicinal composition with anti-infective and antiviral functions |
| 06/15/2011 | CN1930145B Cycloalkanopyridine derivative |
| 06/15/2011 | CN1918129B Therapeutic agent |
| 06/15/2011 | CN1889983B Silver coatings and methods of manufacture |